Comparative Antimicrobial Susceptibility of Gram-Negative Bacteria Isolated from Patients with Bloodstream Infections and Pneumonia When Tested against Tazobactam Combinations

Comparative Antimicrobial Susceptibility of Gram-Negative Bacteria Isolated from Patients with Bloodstream Infections and Pneumonia When Tested against Tazobactam Combinations. Lead author: CG Carvalhaes, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #2192

Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2018

Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2018. Lead author: MA Pfaller, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster # 2115

Ceftolozane-Tazobactam Activity against Difficult-to-Treat Resistance in Pseudomonas aeruginosa from Bloodstream Infections in US Hospitals

Ceftolozane-Tazobactam Activity against Difficult-to-Treat Resistance in Pseudomonas aeruginosa from Bloodstream Infections in US Hospitals. Lead author: D Shortridge, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1589

Minocycline Activity against Stenotrophomonas maltophilia Isolated from Patients in US Hospitals

Minocycline Activity against Stenotrophomonas maltophilia Isolated from Patients in US Hospitals. Lead author: D Shortridge, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1584

Comparison of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Activities when Tested against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections

Comparison of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Activities when Tested against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections. Lead author: HS Sader, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster # 1436

Eight Years of Sustained Potency and Activity of Oritavancin against Gram-Positive Isolates Causing Bacteremia and Endocarditis in the USA, Including Enterococcal Infections Requiring an Optimized Dosing Strategy for Daptomycin

Eight Years of Sustained Potency and Activity of Oritavancin against Gram-Positive Isolates Causing Bacteremia and Endocarditis in the USA, Including Enterococcal Infections Requiring an Optimized Dosing Strategy for Daptomycin. Lead author: CG Carvalhaes, presented at ID Week 2019, October 2-6, Washington DC, USA
Poster #1583

Antimicrobial Activity of Novel β-Lactamase Inhibitor Combinations Tested against Organisms Causing Complicated Urinary Tract Infections in United States Medical Centers

Antimicrobial Activity of Novel β-Lactamase Inhibitor Combinations Tested against Organisms Causing Complicated Urinary Tract Infections in United States Medical Centers. Lead author: HS Sader, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1445

Delafloxacin Activity against Drug-Resistant Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis from US Medical Centers (2014-2018)

Delafloxacin Activity against Drug-Resistant Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis from US Medical Centers (2014-2018). Lead author: D Shortridge, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1582

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Gram-Negative Organisms Isolated from Patients with Bloodstream Infections in United States Medical Centers (2017-2018)

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Gram-Negative Organisms Isolated from Patients with Bloodstream Infections in United States Medical Centers (2017-2018). Lead author: CG Carvalhaes, presented at ID Week 2019, October 2-6, Washington, D. C., USA
Poster #129

Activity of a Novel Polymyxin Analog, QPX9003, Tested against Resistant Gram-Negative Pathogens, Including Carbapenem-Resistant Acinetobacter, Enterobacterales, and Pseudomonas

Activity of a Novel Polymyxin Analog, QPX9003, Tested against Resistant Gram-Negative Pathogens, Including Carbapenem-Resistant Acinetobacter, Enterobacterales, and Pseudomonas. Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #690

Comparison of MIC Results for Gepotidacin by Agar Dilution and Broth Microdilution Methods

Comparison of MIC Results for Gepotidacin by Agar Dilution and Broth Microdilution Methods. Lead author: SJ Ryan Arends, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #701

β-Lactam Resistance Mechanisms in Pseudomonas aeruginosa Isolates Analyzed Using Whole Genome Sequencing (WGS) and Transcriptome Analysis and Their Impact in Resistance to New β-Lactam/β-Lactamase Inhibitors

β-Lactam Resistance Mechanisms in Pseudomonas aeruginosa Isolates Analyzed Using Whole Genome Sequencing (WGS) and Transcriptome Analysis and Their Impact in Resistance to New β-Lactam/β-Lactamase Inhibitors. Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington DC, USA
Poster #600

Epidemiologic Analysis of a Worldwide Collection of Escherichia coli ST131 Using the 1928D Core Genome Multilocus Sequence Typing Reveals Country Specific and Globally Disseminated Clades

Epidemiologic Analysis of a Worldwide Collection of Escherichia coli ST131 Using the 1928D Core Genome Multilocus Sequence Typing Reveals Country Specific and Globally Disseminated Clades. Lead author: LM Deshpande, presented at ID Week 2019, October 2-6, Washington DC, USA
Poster #239

In vitro Activity of Omadacycline against Recent (2018) Bacterial Pathogens Obtained from the United States and Europe from Skin and Skin Structure, Respiratory, and Urinary Tract Infections

In vitro Activity of Omadacycline against Recent (2018) Bacterial Pathogens Obtained from the United States and Europe from Skin and Skin Structure, Respiratory, and Urinary Tract Infections. Lead author: MD Huband, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #665

Activity of Novel β-Lactamase Inhibitor QPX7728 Combined with β-Lactam Agents When Tested against Carbapenem-Resistant Enterobacterales (CRE) Isolates

Activity of Novel β-Lactamase Inhibitor QPX7728 Combined with β-Lactam Agents When Tested against Carbapenem-Resistant Enterobacterales (CRE) Isolates. Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #677

Ceftobiprole Activity against Pathogens Causing Bacterial Skin and Skin Structure Infections in the United States from 2016 through 2018

Ceftobiprole Activity against Pathogens Causing Bacterial Skin and Skin Structure Infections in the United States from 2016 through 2018. Lead author: LR Duncan, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster# T-67

Cefepime-Zidebactam (WCK 5222) Activity against Clinical Isolates of Non-Fermentative Gram-Negative Bacilli Collected Worldwide in 2018

Cefepime-Zidebactam (WCK 5222) Activity against Clinical Isolates of Non-Fermentative Gram-Negative Bacilli Collected Worldwide in 2018. Lead author: HS Sader, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster 69

Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) against Clinical Isolates of Carbapenem-Resistant Enterobacterales Collected Worldwide in 2018

Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) against Clinical Isolates of Carbapenem-Resistant Enterobacterales Collected Worldwide in 2018. Lead author: HS Sader, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster 70

In vitro Activity of the Orally Bioavailable Ceftibuten/VNRX-7145 Combination against a Challenge Set of Enterobacteriaceae Pathogens Carrying Molecluarly Characterized β-Lactamase Genes

In vitro Activity of the Orally Bioavailable Ceftibuten/VNRX-7145 Combination against a Challenge Set of Enterobacteriaceae Pathogens Carrying Molecluarly Characterized β-Lactamase Genes. Lead author: RE Mendes, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster #73

In Vitro Activity of KHP-3757 and Comparators against Recent and Molecularly Characterized Pseudomonas aeruginosa Isolates from a Global Surveillance Program

In Vitro Activity of KHP-3757 and Comparators against Recent and Molecularly Characterized Pseudomonas aeruginosa Isolates from a Global Surveillance Program. Lead author: MD Huband, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster

Omadacycline Is Not a Substrate for Clinically Relevant β-Lactamase Enzymes

Omadacycline Is Not a Substrate for Clinically Relevant β-Lactamase Enzymes. Lead author: RE Mendes, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster # W-62

Activity of KBP-7072 against Recent and Molecularly Characterized Acinetobacter baumannii Isolates

Activity of KBP-7072 against Recent and Molecularly Characterized Acinetobacter baumannii Isolates. Lead author: MD Huband, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster # W-69

Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the United States from 2014 through 2016.

Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the United States from 2014 through 2016. by Duncan LR, Smith CJ, Flamm RK and Mendes RE. published in J. Glob. Antimicrob. Resist.: in press, 2019.

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015-2017).

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015-2017). by Sader HS, Castanheira M, Streit JM and Flamm RK. published in Diag. Microbio. Infect. Dis.: in press, 2019.

The microbiology of bloodstream infection: 20-year trends from the SENTRY Antimicrobial Surveillance Program.

The microbiology of bloodstream infection: 20-year trends from the SENTRY Antimicrobial Surveillance Program. by Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS and Jones RN. published in Antimicrob. Agents Chemother. 2019; 63 (7): e00355

Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin and fosfomycin against well characterized multi-drug resistant K. pneumoniae and P. aeruginosa.

Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin and fosfomycin against well characterized multi-drug resistant K. pneumoniae and P. aeruginosa. by Mikhail S, Singh NB, Kebriaei R, Rice SA, Stamper KC, Castanheira M and Rybak MJ. Antimicrob. Agents Chemother. 2019; 63 (8): e00779

Determination of MIC quality control ranges for the novel gyrase inhibitor, zoliflodacin.

Determination of MIC quality control ranges for the novel gyrase inhibitor, zoliflodacin. by Miller A, Traczewski T, Huband M, Bradford P and Mueller J. published in J. Clin. Microbiol, 2019 57 (9): e00567

Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals.

Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals. by Castanheira M, Doyle TB, Smith CJ, Mendes RE and Sader HS. published in J. Antimicrob. Chemother. 2019; 74 (9): 2588-2595

Ceftibuten-Avibactam Activity against β-Lactam-Resistant Enterobacteriaceae Clinical Isolates

Ceftibuten-Avibactam Activity against β-Lactam-Resistant Enterobacteriaceae Clinical Isolates. Lead author LR Duncan, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-717

Antimicrobial Activity of Ceftibuten-Clavulanate When Tested against Clinical Enterobacterales Isolates Collected Worldwide in 2017

Antimicrobial Activity of Ceftibuten-Clavulanate When Tested against Clinical Enterobacterales Isolates Collected Worldwide in 2017. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-718

Antimicrobial Activity of Plazomicin Tested against a Worldwide Collection of Enterobacterales Isolated from Patients with Complicated Urinary Tract Infections (2014-2017)

Antimicrobial Activity of Plazomicin Tested against a Worldwide Collection of Enterobacterales Isolated from Patients with Complicated Urinary Tract Infections (2014-2017). Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-591

Correlation between Broth Microdilution and Disk Diffusion Results When Testing Ceftazidime-Avibactam against a Challenge Collection of Enterobacterales: Results from a Multi-Laboratory Study

Correlation between Broth Microdilution and Disk Diffusion Results When Testing Ceftazidime-Avibactam against a Challenge Collection of Enterobacterales: Results from a Multi-Laboratory Study. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-CPHM-866

Plazomicin is Active against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases, Carbapenemases, and Aminoglycoside-Modifying Enzymes from United States (US) Hospitals

Plazomicin is Active against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases, Carbapenemases, and Aminoglycoside-Modifying Enzymes from United States (US) Hospitals. Lead author: M Castanheira, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-596

Cefepime-Zidebactam (WCK 5222) Activity against Clinical Isolates of Non-Fermentative Gram-Negative Bacilli Collected Worldwide in 2018

Cefepime-Zidebactam (WCK 5222) Activity against Clinical Isolates of Non-Fermentative Gram-Negative Bacilli Collected Worldwide in 2018. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-730

Antimicrobial Activity of High-Dose Extended-Infusion Cefepime-Tazobactam (WCK 4282) Tested against Gram-Negative Organisms Collected from Medical Centers in the United States and Latin America (2018)

Antimicrobial Activity of High-Dose Extended-Infusion Cefepime-Tazobactam (WCK 4282) Tested against Gram-Negative Organisms Collected from Medical Centers in the United States and Latin America (2018). Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-599

Activity of Meropenem-Vaborbactam and Characterization of Carbapenem Resistance Mechanisms among Carbapenem-Resistant Enterobacteriaceae from United States Hospitals (2016-2017)

Activity of Meropenem-Vaborbactam and Characterization of Carbapenem Resistance Mechanisms among Carbapenem-Resistant Enterobacteriaceae from United States Hospitals (2016-2017). Lead author: M Castanheira, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-594

Ceftibuten-Clavulanate Activity against Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae

Ceftibuten-Clavulanate Activity against Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Saturday-AAR-780

Cefepime-Zidebactam (WCK 5222) Activity when Tested against Enterobacterales Isolated from Patients Hospitalized in the United States and Latin America in 2018

Cefepime-Zidebactam (WCK 5222) Activity when Tested against Enterobacterales Isolated from Patients Hospitalized in the United States and Latin America in 2018. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA
# Saturday-AAR-754

In Vitro Activity of Tedizolid and Comparator Agents against Gram-Positive Isolates Causing Bloodstream Infections in US and European Hospitals (2018)

In Vitro Activity of Tedizolid and Comparator Agents against Gram-Positive Isolates Causing Bloodstream Infections in US and European Hospitals (2018). Lead Author: C Carvalhaes, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
#Saturday-AAR-612

Evaluation of Tebipenem Activity Tested against a Collection of Isogenic Escherichia coli Strains Producing Various Clinically Relevant β-Lactamases

Evaluation of Tebipenem Activity Tested against a Collection of Isogenic Escherichia coli Strains Producing Various Clinically Relevant β-Lactamases. Lead author: LM Deshpande, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Saturday-AAR-778

Tedizolid In Vitro Activity against a Collection of Multidrug-Resistant Gram-Positive Clinical Isolates from US Medical Centers (2017-2018)

Tedizolid In Vitro Activity against a Collection of Multidrug-Resistant Gram-Positive Clinical Isolates from US Medical Centers (2017-2018). Lead author: C Carvalhaes, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Saturday-AAR-611

Monitoring the In Vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, against a Current Collection of Surveillance Enterobacterales Clinical Isolates (2018)

Monitoring the In Vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, against a Current Collection of Surveillance Enterobacterales Clinical Isolates (2018). Lead author: RE Mendes, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
#Saturday-AAR-777

Ceftobiprole Activity against Pathogens Causing Bacterial Skin and Skin Structure Infections in the United States from 2016 through 2018

Ceftobiprole Activity against Pathogens Causing Bacterial Skin and Skin Structure Infections in the United States from 2016 through 2018. Lead author: LR Duncan, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Saturday-AAR-607

Activity of Investigational Polymyxin-B-Like Compound (SPR206) against Set of Gram-Negative Bacilli Responsible for Human Infections

Activity of Investigational Polymyxin-B-Like Compound (SPR206) against Set of Gram-Negative Bacilli Responsible for Human Infections. Lead author: SJR Arends, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Friday-AAR-796

Susceptibility Trends of Ceftolozane-Tazobactam and Comparators When Tested against US Gram-Negative Bacterial Surveillance Isolates Collected from 2012-2018

Susceptibility Trends of Ceftolozane-Tazobactam and Comparators When Tested against US Gram-Negative Bacterial Surveillance Isolates Collected from 2012-2018. Lead author: D Shortridge, presented at ASM Microbe 2019, June 20-24, San Francisco, CA USA
#Friday-AAR-538

In Vitro Activity of Omadacycline and Comparators against Gram-positive and -Negative Isolates Collected from Patients in United States Medical Centers (2018): SENTRY Surveillance Program Results

In Vitro Activity of Omadacycline and Comparators against Gram-positive and -Negative Isolates Collected from Patients in United States Medical Centers (2018): SENTRY Surveillance Program Results. Lead author: MD Huband presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Friday-AAR-540

Update on the In Vitro Activity of Dalbavancin against Indicated Species (Staphylococcus aureus, Enterococcus Faecalis, β-Hemolytic Streptococci, and Streptococcus anginosus Group) Collected from United States Hospitals in 2017-2018

Update on the In Vitro Activity of Dalbavancin against Indicated Species (Staphylococcus aureus, Enterococcus Faecalis, β-Hemolytic Streptococci, and Streptococcus anginosus Group) Collected from United States Hospitals in 2017-2018. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Friday-AAR-542

In vitro activity of APX001A (manogepix) and comparator agents against 1,706 fungal isolates collected during an international surveillance program (2017).

In vitro activity of APX001A (manogepix) and comparator agents against 1,706 fungal isolates collected during an international surveillance program (2017). by Pfaller MA, Huband MD, Flamm RK, Bien PA and Castanheira M. published in Antimicrob. Agents Chemother. 2019; 63 (8), e00840

Comparison of the in vitro susceptibility of ceftolozane-tazobactam to the cumulative susceptibility rates of standard antibiotic combinations when tested against Pseudomonas aerugionsa from ICU patients with bloodstream infections or pneumonia.

Comparison of the in vitro susceptibility of ceftolozane-tazobactam to the cumulative susceptibility rates of standard antibiotic combinations when tested against Pseudomonas aerugionsa from ICU patients with bloodstream infections or pneumonia. by Shortridge D, Pfaller MA, Arends SJR, Raddatz J, DePestel DD and Flamm RK. published in Open Forum Infect. Dis. 20196 (6): ofz240

Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).

Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018). by Sader HS, Flamm RK, Carvalhaes CG and Castanheira M. published in Diagn. Microbiol. Infect. Dis.: in press, 2020; 96: 114833